- Home
- EQS vs ANEB Comparison
EQS vs ANEB Comparison
Compare EQS & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EQS | ANEB |
|---|---|---|
| Founded | 1991 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 19.4M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EQS | ANEB |
|---|---|---|
| Price | $1.37 | $0.48 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.7K | ★ 73.9K |
| Earning Date | 01-01-0001 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $0.44 |
| 52 Week High | $2.49 | $3.42 |
Technical Indicators
Market Signals| Indicator | EQS | ANEB |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 20.90 |
| Support Level | $1.26 | $0.44 |
| Resistance Level | $1.37 | $0.50 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 85.63 | 4.64 |
Price Performance
Historical ComparisonAbout EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.